Core Insights - Akeso, Inc. has initiated a Phase III clinical trial (AK112-311/HARMONi-9) for ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, targeting small cell lung cancer (SCLC) [1][2] - This trial is the eighth registrational Phase III study for ivonescimab in lung cancer, expanding its therapeutic coverage across various indications and treatment lines [2] - SCLC accounts for approximately 15% of all lung cancers, with limited-stage SCLC (LS-SCLC) representing around 30% of cases, highlighting a significant unmet clinical need [3] Company Overview - Akeso is a leading biopharmaceutical company founded in 2012, focused on developing innovative biological medicines and has a robust pipeline of over 50 assets in various disease areas [8][9] - The company employs a unique integrated R&D innovation system, including the ACE Platform and Tetrabody technology, to drive its drug development efforts [8] - Akeso has 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies, and has commercially available 7 new drugs [9]